PhiTech operates a clinical decision-support platform called G&M (Genomik ve Dahası) that simultaneously analyzes patients’ DNA (genomic) and RNA (transcriptomic) sequencing data to produce actionable results for hospitals, genetic diagnostic laboratories and pharmaceutical companies. The platform aims to increase diagnostic yield in complex cases where DNA-only tests are insufficient, and the company reports that many previously undiagnosed patients in Turkey reached correct diagnoses using its system in the past year. PhiTech maintains its research and development center in Turkey and has offices in the United States and the Netherlands, while pursuing international patent applications for its software. With the newly raised $2.4 million, the company plans to broaden market adoption of its rare-disease solutions and finalize research programs for cancer-directed products. Founding scientific leaders include Dr. Saliha Durmuş, Prof. Dr. Tunahan Çakır and Prof. Dr. Erdoğan Sevilgen.

Total raised

$4M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2026